Recent Updates
Recently added Catalysts

IO Biotech, Inc.

IOBT
Fair ValueBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$0
▲ +0.02 · +68.42%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IOBT financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.0352W HIGH $2.79
Volume
33.69 K
Value Traded
3.41
Short % Float
15.48%
-75.56%Week
-84.64%1 Month
-92.07%3 Month
-90.46%6 Month
-99.7%5 Year
-99.7%All Time

Cash Data

Unlock IOBT cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.45 M
EPS (TTM)
-1.34
P/E Ratio
-
Ent. Value
-9.09 M
Total Shares
72.06 M
Float Shares
13.91 M
Insiders
16.12%
Institutions
40.08%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every IOBT catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IOBT Catalyst Timeline

Dated clinical, regulatory and corporate events for IO Biotech, Inc.

Unlock the full IOBT catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IOBT actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-09-30Cylembio® (imsapepimut and etimupepimut, adjuvanted) Phase 3 data readout Phase 3
Unlock 1 more IOBT historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D31 / 100
Pipeline Score
$3M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
1.0x
rNPV / MCap
IO Biotech, Inc. faces pipeline headwinds (31/100), with $1.1B risk-adjusted pipeline value, led by IO102-IO103 in Lung Cancer Non Small Cell (Phase 2), across $58B in total addressable markets, but cash runway is a concern.
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
IO102-IO103 Small moleculeNCT05155254Metastatic MelanomaPhase 3 ACTIVE NOT_RECRUITING 407Sep 1, 2027
Unlock the IOBT pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IOBT program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IO102-IO103
Breakthrough
metastatic melanomaPhase 1/22025-12-15median progression free survival: 25.5 months; median overall survival: 60 months; median duration of response: more than 53 monthsRead MoreIO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsRead More
Scroll for more · summaries link to the source press release
Unlock every IOBT trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IOBT insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Hunter HeidiDirectorBuy 15,000 15,000 held$1.39 05/30/2025
Unlock the full IOBT insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in IOBT

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0 % (-100 %) 81.00 K 1.39 M
Unlock every fund holding IOBT
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IOBT
Shares held by hedge funds each quarter, and who bought or sold.

IOBT Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock IOBT option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IOBT option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IOBT options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IOBT ranks across every disease it competes in

Competitive Position is a premium feature
See how IOBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IOBT News

About IO Biotech, Inc.

Copenhagen, G7 78 employees iobiotech.com
HeadquartersOLE MAALOES VEH 3, COPENHAGEN, G7, 2200
Founded2014
BIOPHARMAWATCH ELITE PLUS
Trade the next IOBT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime